Superbugs & You

<p>Listen to a recording of our roundtable webinar on the impact of antimicrobial resistance (AMR) in cancer care. Experts discuss recent research, share key takeaways, and explore how stewardship and infection prevention can help protect patients.</p>
<p>&nbsp;</p>

<p>One Health is a concept that recognizes this interconnection and emphasizes the need for collaborative approaches to solving the issue of antimicrobial resistance at all levels - &nbsp;humans, animals, and the environment is undeniable. Guests on this episode include Lance Price, (George Washington University), Francisco Diez-Gonzales (University of Georgia), and Paul Plummer (Iowa State University, NIAMRRE).</p>
<p>&nbsp;</p>

<p>Antimicrobials are the cornerstone of modern medicine, and this is especially true for patients with cystic fibrosis. People with CF rely on antibiotics for recurring and persistent infections, and with regular use, antibiotics become less and less effective in fighting these infections. Guests include Ella Balasa, (Patient Advocate), Helen Boucher, MD (Tufts Medicine), and Mary Booth Dwight (Cystic Fibrosis Foundation).</p>
<p>&nbsp;</p>

<p><strong>Season 4 of Superbugs and You is here!</strong></p>
<p>Episode 14:&nbsp;This year, Italy leads the Presidency of the G7. The group is united by common values in addressing global challenges, including antimicrobial resistance. This episode features Italian leaders driving transformational policy to battle AMR. Guests include Francesca Chiara, (CIDRAP ASP), Mariano Votta (Active Citizenship Network-Cittadinanzattiva), Damiano De Felice (CARB-X), and Massimo Sartelli (Global Alliance for Infections in Surgery).</p>
<p>&nbsp;</p>

<p>Health officials around the world are sounding the alarm on a highly infectious bacteria causing extensively drug-resistant infections. <em>Shigella</em>, which causes the infection known as shigellosis, is a genus of bacteria that results in gastrointestinal distress that ranges from uncomfortable to deadly, in adults and children. Global surveillance efforts on<em> Shigella</em> have identified outbreaks of strains that are extensively drug-resistant across the UK, US, and parts of Europe. How is the world dealing with this new superbug?</p>
<p>&nbsp;</p>
<p><strong>Guests</strong></p>
<p><strong>Lou Bourgeois, PhD:</strong> Johns Hopkins, Science Officer for Enteric and Diarrheal Diseases, PATH</p>
<p><strong>Gauri Godbole, MBBS, MD:</strong>&nbsp;UKHSA, Consultant Microbiologist and Parasitologist, Hospital for Tropical Diseases, University College London Hospitals, NHS</p>
<p><strong>Naemah Logan, MD:</strong> Medical Officer, Surveillance Epidemiologist, National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS), Centers for Disease Control and Prevention (CDC)</p>
<p><strong>Louise Francois Watkins, MD:</strong> Medical Officer, NARMS, Centers for Disease Control and Prevention: CDC</p>
<p>&nbsp;</p>